David W. VaughnCharles H. HokeSutee YoksanRebecca LaChanceBruce L. InnisRobert M. RiceNatth BhamarapravatiWalter Reed Army Institute of ResearchMahidol UniversityU.S. Army Medical Research Institute of Infectious DiseasesU. States Army Med. Res. Inst. I.2018-07-042018-07-041996-01-01Vaccine. Vol.14, No.4 (1996), 329-3360264410X2-s2.0-0029916970https://repository.li.mahidol.ac.th/handle/20.500.14594/17572A live-attenuated dengue 2 vaccine (strain 16681 PDK 53) developed at Mahidol University, Thailand was evaluated for safety and immunogenicity by administering 104p.f.u. subcutaneously to ten flavivirus non-immune American volunteers. The vaccine was safe; there were no serious adverse reactions. Eight recipients experienced no or mild side effects. One recipient reported headaches on 7 separate days. One volunteer, who had a fracture of the humerus 1 day after vaccination requiring surgical repair, experienced generalized malaise with fever (maximum temperature = 38.9°C), headache, eye pain and myalgia lasting less than 24 h. The vaccine was highly immunogenic; all recipients developed neutralizing antibody that persisted for two years.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyImmunology and MicrobiologyMedicineVeterinaryArticleSCOPUS10.1016/0264-410X(95)00167-Y